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The persistence of the malaria parasite 
P. falciparum during the proliferation 
phase in red blood cells of its human 
host depends on the successive 
expression of variant molecules on the 
surface of the infected erythrocytes. 
This variation is mediated by the dif-
ferential expression of a polymorphic 
parasite protein, P. falciparum eryth-
rocyte membrane protein 1 (PfEMP1), 
which is encoded by 60 var genes. 
Antigenic variation of PfEMP1 is a 
major mechanism that the malaria 
parasite uses to evade attack by host 
antibodies. It is generally assumed that 
a better understanding of this mecha-
nism might reveal a new Achilles’ heel 
that could be exploited for developing 
therapeutics against P. falciparum. 
A recent paper in Nature (Voss et al., 
2005) suggests that an active var pro-
moter by itself is sufficient to silence 
endogenous var genes and to ensure 
monoallelic expression of a single var
gene (see Figure 1).
Since the discovery of the var gene 
family in 1995 by the Wellems labora-
tory (Su et al., 1995), a basic molecu-
lar understanding of malaria parasite 
antigenic variation has been achieved. 
Early evidence for epigenetic con-
trol of antigenic variation came from a 
study showing that var gene switching 
occurs in situ from telomeric and cen-
tral var gene locations without any pro-
grammed DNA rearrangements (Scherf 
et al., 1998). Furthermore, nuclear run-
on analyses showed that in situ var
gene expression is controlled at the 
level of transcriptional initiation. Subse-
quently, data from reporter constructs 
suggested that var promoter silencing 
requires an intron located between 
exons 1 and 2 (Deitsch et al., 2001).
Although our understanding of P. 
falciparum epigenetics is still in its 
infancy, it is increasingly evident that 
antigenic variation is controlled by a 
number of different factors. P. falci-
parum telomeric regions promote the 
nucleation of silencing factors such 
as a protein homologous to the Sir2 
(silent information regulator 2) protein 
of the yeast Saccharomyces cerevi-
siae. Histone acetylation and the P. fal-
ciparum homolog of Sir2, PfSir2, mark 
var gene promoters for monoallelic 
var gene expression (Freitas-Junior et 
al., 2005). Moreover, subtelomeric var
genes are switched on in PfSir2 mutant 
parasites, whereas var genes located 
in central chromosomal regions gen-
erally remain silent (Duraisingh et al., 
2005). The remodeling of var promot-
ers by histone modifications is likely to 
be involved in the silencing of all var
genes, whereas silencing by PfSir2 
applies to only a subset of telomeric 
var genes (for review, see Ralph and 
Scherf [2005]). This is also reflected in 
the perinuclear location of var genes. 
In general, subtelomeric var genes are 
associated with telomeric clusters, 
whereas var genes in central chro-
mosomal regions apparently are not 
(Ralph et al., 2005).
In addition to changes in chromatin 
at promoters, other types of epigen-
etic modifications are a prerequisite 
for var gene activation. For example, 
the relocation of a telomeric var gene 
into a transcriptionally competent peri-
nuclear region has been observed 
(Duraisingh et al., 2005; Ralph et al., 
2005). Although the nature of this peri-
nuclear transcription zone remains elu-
sive, analysis of serial sections of P. fal-
ciparum nuclei by electron microscopy 
revealed a perinuclear region that is in 
fact devoid of heterochromatin (S.A. 
Ralph and A.S., unpublished data). 
Thus, it appears that var transcription 
is a consequence of positioning var
genes into regions of euchromatin at 
the periphery of the nucleus.
Despite the variety of epigenetic 
factors that control central and telo-
meric var gene activation, it is impor-
tant to keep in mind that basically all 
var genes obey the rule of allelic exclu-
sion and must therefore be linked by 
a common mechanism when it comes 
to the switching of expression to a 
single member of this gene family. The 
genetic control elements that deter-
mine mutually exclusive expression 
remain elusive. In their recent Nature
article, Voss et al. (2005) identified 
a single genetic element of the var
gene transcriptional unit that mediates 
silencing of a transgene (in this case 
a selectable drug resistance marker 
gene). Once activated by the drug, 
the transgene promoter is sufficient 
to silence endogenous var genes. The 
most surprising result is that a var pro-
moter driving the selection transgene 
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Immune evasion by the malaria parasite Plasmodium falciparum is mediated by the mutu-
ally exclusive expression of a single member of the var family of genes, which encode 
variant surface antigens. In a recent paper in Nature, Voss et al. (2005) demonstrate that 
a construct carrying a transcriptionally active var promoter is sufficient to promote allelic 
exclusion of the parasite’s endogenous var gene.
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(human dihyrofolate reduc-
tase, hDHFR) from an epi-
some is able to infiltrate the 
var gene allelic exclusion 
program to silence endog-
enous var genes. It remains 
to be seen whether silenc-
ing by PfSir2-dependent 
var promoters (type upsA) 
is also independent of chro-
mosomal integration. Hav-
ing the ability to silence the 
expression of the immuno-
dominant surface molecule 
encoded by var genes now 
opens up the possibility of 
exploring the role of other 
variant surface molecules 
in malaria pathology.
The work of Voss and 
colleagues challenges pre-
vious work on intron-medi-
ated var promoter silencing 
(see Figure 1; Deitsch et al., 
2001; Gannoun-Zaki et al., 
2005). The role that was 
postulated earlier for the var
intron in silencing needs to 
be reexamined in the light 
of these new data, which 
clearly demonstrate that 
there is no absolute require-
ment for the intron to silence 
or activate a var promoter 
controlling a transgene. Can 
this new data be reconciled 
with the previous reports? 
The major difference in 
experimental design is that 
in the Voss et al. (2005) 
study, the var promoter is 
forced via drug selection to 
transcribe a drug resistance 
marker gene at high rates 
(see Figure 1). This is not the 
case in the transient lucifer-
ase assays used by Deitsch 
and colleagues (2001), which probably 
measures a weak var promoter activ-
ity in the presence of an active endog-
enous var gene. Thus, the intron may 
have the strength to silence a weakly 
transcribed var promoter. It is reason-
able to propose that the intron has a 
more subtle role in enhancing repres-
sion of the var promoter.
The var genes located in central 
chromosomal regions are found in 
several clusters. However, when a sin-
gle member of this cluster is activated, 
other var genes in the direct vicinity 
remain silenced. How this is achieved 
remains enigmatic. The data of Voss 
et al. (2005) show that the presence 
of the intron in the episome efficiently 
reduces the transcription of the sec-
ond selectable marker gene encod-
ing blasticidin. This suggests that var
introns are barriers to transcription. 
Obviously, the creation of 
an intronless endogenous 
var gene in its chromosomal 
context should tell us more 
about the biological role of 
the var intron.
However, the strict rule 
that var promoter tran-
scription is mutually exclu-
sive can be overcome 
experimentally. Synthetic 
var genes are transcribed 
from heterologous promot-
ers on episomes without 
silencing the endogenous 
var gene (N.K. Viebig, B. 
Gamain, and A.S., unpub-
lished data). This further 
supports the role of the var
promoter as the key genetic 
element that controls allelic 
exclusion. A recent report, 
however, demonstrates that 
two endogenous var pro-
moters can be active at the 
same time under specific 
experimental conditions, 
one being the promoter 
for the normally expressed 
var gene and the other the 
promoter for a second var
gene (var2CSA) that is nor-
mally silent. The integration 
of an active DHFR expres-
sion cassette approximately 
4 kb downstream from the 
normally silent var2CSA 
promoter leads to truncated 
var2CSA transcripts (Viebig 
et al., 2005). How the allelic 
exclusion control system 
is defeated by this event 
remains unclear. This result, 
however, demonstrates the 
fragility of the parasite’s 
allelic exclusion system, and 
it may be wise to interpret 
data obtained from transgene var tran-
scription experiments with caution.
What emerges from the Voss et al. 
(2005) study is that a single genetic 
element located upstream of var genes 
apparently contains all of the informa-
tion necessary to activate var genes 
in a mutually exclusive manner. This is 
a big step forward in trying to under-
stand a puzzling biological concept 
that is a Holy Grail in many research 
Figure 1. The var Promoter and Intron Regions Control P. 
falciparum Transgene Transcription
The two panels summarize studies on var promoters driving different 
types of reporter genes in transfected blood stage malaria parasites either 
as episomes or integrated into a “central” var locus on chromosome 12.
(A) In the Voss et al. (2005) study, P. falciparum was stably transfected 
with plasmids carrying two drug-selectable markers. Blasticidin was 
used for the stable maintenance of the plasmid and human dihyrdofo-
late reductase, hDHFR—which confers resistance to the drug WR99210 
(WR)—was used to analyze var promoter function in its silent state (−WR, 
top panel) and active state (+WR, bottom panel). Silencing of endog-
enous var genes required active transcription from the var promoter of 
the transgene, but did not require the presence of the var intron, nor did 
it require chromosomal integration. (nd = not determined).
(B) Deitsch et al. (2001) used a transient reporter assay comprising the 
luciferase gene driven by a central var promoter in the absence or pres-
ence of a var intron sequence. In this experiment, the var intron silenced 
transgene expression from the var promoter.
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areas, including the field of molecu-
lar parasitology (Borst, 2002). We 
hope that other enigmatic epigenetic 
mechanisms, such as those that con-
trol variable rates of var gene switching 
(Horrocks et al., 2004) will not remain 
an eternal mystery.
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The migration of hematopoietic stem 
cells (HSCs) is evident in several cir-
cumstances. During development, 
HSCs seed new sites of hematopoi-
esis, and under physiological condi-
tions in adult life, HSCs continuously 
move between the bone marrow 
and the bloodstream. Also, a mas-
sive efflux of HSCs, a process called 
mobilization, occurs following treat-
ment with cytotoxic drugs or cytokines 
such as granulocyte colony-stimulat-
ing factor (G-CSF), whereas follow-
ing intravenous injection into trans-
plant recipients, HSCs migrate to and 
engraft in the bone marrow. Although 
the mobilization and transplantation of 
HSCs is widely used in modern clini-
cal medicine, the precise mechanisms 
by which HSCs exit their niche or re-
engage their niche after transplanta-
tion are still being unraveled. Katayama 
et al. (2006) now report that the sym-
pathetic nervous system is a key and 
previously unrecognized participant in 
HSC mobilization.
As a result of more than four decades 
of studies using mostly rodent models 
and an equally long clinical tradition 
of bone-marrow transplantation regi-
mens, HSCs are the best characterized 
population of stem cells. However, the 
field has been held back by an impre-
cise understanding of the microenvi-
ronment, or niche, in which the HSCs 
reside. This, for obvious reasons, has 
hampered detailed investigation of the 
mobilization and engraftment process. 
Studies of the HSC microenvironment 
have been limited by the fact that the 
most liquid of tissues, bone marrow, is 
encased by the most solid. By label-
ing stem cells and reinfusing them, it 
has been shown that HSCs reside in 
close proximity to the endosteal bone 
surface, and the assumption has been 
made that maturing cells become 
redistributed toward the central marrow 
region. Recently, two genetic studies 
identified osteoblasts as crucial cellu-
lar components of the HSC microenvi-
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In this issue of Cell, Katayama et al. (2006) report a new regulatory axis for the mobiliza-
tion of hematopoietic stem cells that links these cells to the nervous system and bone in 
an unanticipated way. The new findings suggest that the nervous system, which has the 
inherent ability to integrate information from throughout the organism, may govern the local 
relationship between stem cells and their niches.
